<DOC>
	<DOCNO>NCT00170911</DOCNO>
	<brief_summary>AAE581 specific inhibitor cysteine protease cathepsin K. This trial design provide detail information effect ( efficacy safety ) AAE581 Bone Mineral Density .</brief_summary>
	<brief_title>Efficacy Safety AAE581 Postmenopausal Women With Osteopenia/Osteoporosis .</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<criteria>Low spine Bone Mineral Density 0 1 prevalent fracture non lumber spine History presence bone disease osteopenia /osteoporosis Previous treatment antiosteoporosis agent ( Wash require ) Evidence vitamin D deficiency Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Postmenopausal woman</keyword>
	<keyword>Cathepsin K inhibitor</keyword>
</DOC>